Genetic analysis of obstructive sleep apnoea discovers a strong association with cardiometabolic health
- PMID: 33243845
- DOI: 10.1183/13993003.03091-2020
Genetic analysis of obstructive sleep apnoea discovers a strong association with cardiometabolic health
Abstract
There is currently limited understanding of the genetic aetiology of obstructive sleep apnoea (OSA). We aimed to identify genetic loci associated with OSA risk, and to test if OSA and its comorbidities share a common genetic background.We conducted the first large-scale genome-wide association study of OSA using the FinnGen study (217 955 individuals) with 16 761 OSA patients identified using nationwide health registries.We estimated 0.08 (95% CI 0.06-0.11) heritability and identified five loci associated with OSA (p<5.0×10-8): rs4837016 near GAPVD1 (GTPase activating protein and VPS9 domains 1), rs10928560 near CXCR4 (C-X-C motif chemokine receptor type 4), rs185932673 near CAMK1D (calcium/calmodulin-dependent protein kinase ID) and rs9937053 near FTO (fat mass and obesity-associated protein; a variant previously associated with body mass index (BMI)). In a BMI-adjusted analysis, an association was observed for rs10507084 near RMST/NEDD1 (rhabdomyosarcoma 2 associated transcript/NEDD1 γ-tubulin ring complex targeting factor). We found high genetic correlations between OSA and BMI (rg=0.72 (95% CI 0.62-0.83)), and with comorbidities including hypertension, type 2 diabetes, coronary heart disease, stroke, depression, hypothyroidism, asthma and inflammatory rheumatic disease (rg>0.30). The polygenic risk score for BMI showed 1.98-fold increased OSA risk between the highest and the lowest quintile, and Mendelian randomisation supported a causal relationship between BMI and OSA.Our findings support the causal link between obesity and OSA, and the joint genetic basis between OSA and comorbidities.
Copyright ©ERS 2021. For reproduction rights and permissions contact permissions@ersnet.org.
Conflict of interest statement
Conflict of interest: S. Strausz has nothing to disclose. Conflict of interest: S. Ruotsalainen has nothing to disclose. Conflict of interest: H.M. Ollila has nothing to disclose. Conflict of interest: J. Karjalainen has nothing to disclose. Conflict of interest: T. Kiiskinen has nothing to disclose. Conflict of interest: M. Reeve has nothing to disclose. Conflict of interest: M. Kurki has nothing to disclose. Conflict of interest: N. Mars has nothing to disclose. Conflict of interest: A.S. Havulinna has nothing to disclose. Conflict of interest: E. Luonsi has nothing to disclose. Conflict of interest: D. Mansour Aly has nothing to disclose. Conflict of interest: E. Ahlqvist has nothing to disclose. Conflict of interest: M. Teder-Laving has nothing to disclose. Conflict of interest: P. Palta has nothing to disclose. Conflict of interest: L. Groop has nothing to disclose. Conflict of interest: R. Mägi has nothing to disclose. Conflict of interest: A. Mäkitie has nothing to disclose. Conflict of interest: V. Salomaa has received honoraria from Novo Nordisk and Sanofi for consultations and has ongoing research collaboration with Bayer AG (all unrelated to this study). Conflict of interest: A. Bachour has nothing to disclose. Conflict of interest: T. Tuomi has nothing to disclose. Conflict of interest: A. Palotie has nothing to disclose. Conflict of interest: T. Palotie has nothing to disclose. Conflict of interest: S. Ripatti has nothing to disclose.
Comment in
-
Cutting the fat: advances and challenges in sleep apnoea genetics.Eur Respir J. 2021 May 6;57(5):2004644. doi: 10.1183/13993003.04644-2020. Print 2021 May. Eur Respir J. 2021. PMID: 33958377 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical